Connor, Clark & Lunn Investment Management Ltd. Arvinas, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$20 Billion
Q4 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$21.73 - $31.43 $2.2 Million - $3.17 Million	-101,015 Reduced 71.6%	40,076 $994,000
Q1 2023 May 09, 2023	SELL	$26.15 - $37.26 $820,430 - $1.17 Million	-31,374 Reduced 18.19%	141,091 $3.85 Million
Q4 2022 Feb 10, 2023	SELL	$32.47 - $57.24 $624,885 - $1.1 Million	-19,245 Reduced 10.04%	172,465 $5.9 Million
Q3 2022 Nov 10, 2022	BUY	$41.87 - $57.99 $2.88 Million - $3.99 Million	68,782 Added 55.95%	191,710 $8.53 Million
Q2 2022 Aug 05, 2022	BUY	$36.01 - $74.24 $1.53 Million - $3.16 Million	42,578 Added 52.99%	122,928 $5.17 Million
Q1 2022 May 12, 2022	BUY	$60.27 - $81.57 $740,356 - $1 Million	12,284 Added 18.05%	80,350 $5.41 Million
Q4 2021 Feb 10, 2022	BUY	$65.85 - $96.21 $2.45 Million - $3.59 Million	37,280 Added 121.09%	68,066 $5.59 Million
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $2.25 Million - $3.32 Million	30,786 New	30,786 $2.53 Million

Others Institutions Holding ARVN

# of Institutions

224

Shares Held

70.9M

Call Options Held

1.52M

Put Options Held

346K

Vanguard Group Inc Valley Forge, PA

7.06M
Shares

$131 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

6.73M
Shares

$125 Million
6.03% of portfolio
Black Rock Inc. New York, NY

6.26M
Shares

$116 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.1M
Shares

$76.1 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

3.33M
Shares

$61.8 Million
1.04% of portfolio

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account